SITE001-0208

SITE001 (USA) › SITE001-0208

SITE001-0208

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2026-05-04

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-13 (study day 96); relationship: not assessed

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 48); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-05 (study day 26); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.